Reviewing Minerva Neurosciences Inc. (NERV)’s and Precision BioSciences Inc. (NASDAQ:DTIL)’s results

Minerva Neurosciences Inc. (NASDAQ:NERV) and Precision BioSciences Inc. (NASDAQ:DTIL) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Minerva Neurosciences Inc. 5 0.00 33.60M -1.38 0.00
Precision BioSciences Inc. 10 0.00 36.71M -1.39 0.00

Table 1 showcases the top-line revenue, earnings per share (EPS) and valuation of Minerva Neurosciences Inc. and Precision BioSciences Inc.


Table 2 represents Minerva Neurosciences Inc. (NASDAQ:NERV) and Precision BioSciences Inc. (NASDAQ:DTIL)’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
Minerva Neurosciences Inc. 666,666,666.67% -56.4% -36.9%
Precision BioSciences Inc. 371,558,704.45% 0% 0%


Minerva Neurosciences Inc.’s Current Ratio and Quick Ratio are 11.6 and 11.6 respectively. The Current Ratio and Quick Ratio of its competitor Precision BioSciences Inc. are 1.9 and 1.9 respectively. Minerva Neurosciences Inc. therefore has a better chance of paying off short and long-term obligations compared to Precision BioSciences Inc.

Analyst Recommendations

In next table is shown Minerva Neurosciences Inc. and Precision BioSciences Inc.’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Minerva Neurosciences Inc. 0 0 3 3.00
Precision BioSciences Inc. 0 0 0 0.00

Minerva Neurosciences Inc. has a 211.99% upside potential and an average target price of $19.

Insider and Institutional Ownership

Institutional investors held 90.8% of Minerva Neurosciences Inc. shares and 41.6% of Precision BioSciences Inc. shares. 0.7% are Minerva Neurosciences Inc.’s share held by insiders. Competitively, Precision BioSciences Inc. has 19.3% of it’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Minerva Neurosciences Inc. 3.11% 16.29% -8.16% 5.4% -15.95% -1.48%
Precision BioSciences Inc. -0.62% -0.85% -0.54% 0% 0% -26.2%

For the past year Minerva Neurosciences Inc. has stronger performance than Precision BioSciences Inc.


On 6 of the 10 factors Minerva Neurosciences Inc. beats Precision BioSciences Inc.

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of a portfolio of product candidates for the treatment of central nervous system diseases. The companyÂ’s lead product candidate includes MIN-101, a compound for the treatment of patients with schizophrenia that completed Phase IIb clinical trial. It also offers MIN-202, which completed Phase IIa clinical trial for treating primary insomnia, as well as completed Phase 1b used for the treatment of major depressive disorder; and MIN-117, a compound that completed Phase IIa clinical trial for the treatment of patients suffering from major depressive disorder. The companyÂ’ preclinical stage product includes MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of ParkinsonÂ’s disease. Minerva Neurosciences, Inc. has a co-development and license agreement with Janssen Pharmaceutica, N.V. for the development of MIN-202. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was founded in 2007 and is based in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.